Definition for Code SystemResearchStudyPhase

<?xml version="1.0" encoding="UTF-8"?>

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="research-study-phase"/> 
  <meta> 
    <lastUpdated value="2024-11-16T04:44:13.161+11:00"/> 
    <profile value="http://hl7.org/fhir/StructureDefinition/shareablecodesystem"/> 
  </meta> 
  <text> 
    <status value="generated"/> 
    <div xmlns="http://www.w3.org/1999/xhtml">
      <p class="res-header-id">
        <b> Generated Narrative: CodeSystem research-study-phase</b> 
      </p> 
      <a name="research-study-phase"> </a> 
      <a name="hcresearch-study-phase"> </a> 
      <a name="research-study-phase-en-US"> </a> 
      <div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border:
       1px solid #8da1b4; border-radius: 5px; line-height: 60%">
        <p style="margin-bottom: 0px">Last updated: 2022-05-15T16:55:11.085+11:00</p> 
        <p style="margin-bottom: 0px">Profile: 
          <a href="shareablecodesystem.html">Shareable CodeSystem</a> 
        </p> 
      </div> 
      <p> This case-sensitive code system 
        <code> http://hl7.org/fhir/research-study-phase</code>  defines the following codes:
      </p> 
      <table class="codes">
        <tr> 
          <td style="white-space:nowrap">
            <b> Code</b> 
          </td> 
          <td> 
            <b> Display</b> 
          </td> 
          <td> 
            <b> Definition</b> 
          </td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">n-a
            <a name="research-study-phase-n-a"> </a> 
          </td> 
          <td> N/A</td> 
          <td> Trials without phases (for example, studies of devices or behavioral interventions).</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">early-phase-1
            <a name="research-study-phase-early-phase-1"> </a> 
          </td> 
          <td> Early Phase 1</td> 
          <td> Designation for optional exploratory trials conducted in accordance with the United
             States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational
             New Drug (IND) Studies. Formerly called Phase 0.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">phase-1
            <a name="research-study-phase-phase-1"> </a> 
          </td> 
          <td> Phase 1</td> 
          <td> Includes initial studies to determine the metabolism and pharmacologic actions
             of drugs in humans, the side effects associated with increasing doses, and to gain
             early evidence of effectiveness; may include healthy participants and/or patients.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">phase-1-phase-2
            <a name="research-study-phase-phase-1-phase-2"> </a> 
          </td> 
          <td> Phase 1/Phase 2</td> 
          <td> Trials that are a combination of phases 1 and 2.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">phase-2
            <a name="research-study-phase-phase-2"> </a> 
          </td> 
          <td> Phase 2</td> 
          <td> Includes controlled clinical studies conducted to evaluate the effectiveness of
             the drug for a particular indication or indications in participants with the disease
             or condition under study and to determine the common short-term side effects and
             risks.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">phase-2-phase-3
            <a name="research-study-phase-phase-2-phase-3"> </a> 
          </td> 
          <td> Phase 2/Phase 3</td> 
          <td> Trials that are a combination of phases 2 and 3.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">phase-3
            <a name="research-study-phase-phase-3"> </a> 
          </td> 
          <td> Phase 3</td> 
          <td> Includes trials conducted after preliminary evidence suggesting effectiveness of
             the drug has been obtained, and are intended to gather additional information to
             evaluate the overall benefit-risk relationship of the drug.</td> 
        </tr> 
        <tr> 
          <td style="white-space:nowrap">phase-4
            <a name="research-study-phase-phase-4"> </a> 
          </td> 
          <td> Phase 4</td> 
          <td> Studies of FDA-approved drugs to delineate additional information including the
             drug's risks, benefits, and optimal use.</td> 
        </tr> 
      </table> 
    </div> 
  </text> 
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
    <valueCode value="brr"/> 
  </extension> 
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status">
    <valueCode value="trial-use"/> 
  </extension> 
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm">
    <valueInteger value="0"/> 
  </extension> 
  <url value="http://hl7.org/fhir/research-study-phase"/> 
  <version value="6.0.0-ballot2"/> 
  <name value="ResearchStudyPhase"/> 
  <title value="ResearchStudy Phase Code System"/> 
  <status value="active"/> 
  <experimental value="false"/> 
  <date value="2022-05-15T16:55:11.085+11:00"/> 
  <publisher value="HL7 (FHIR Project)"/> 
  <contact> 
    <telecom> 
      <system value="url"/> 
      <value value="http://hl7.org/fhir"/> 
    </telecom> 
    <telecom> 
      <system value="email"/> 
      <value value="fhir@lists.hl7.org"/> 
    </telecom> 
  </contact> 
  <description value="Codes for the stage in the progression of a therapy from initial experimental use
   in humans in clinical trials to post-market evaluation."/> 
  <jurisdiction> 
    <coding> 
      <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/> 
      <code value="001"/> 
      <display value="World"/> 
    </coding> 
  </jurisdiction> 
  <caseSensitive value="true"/> 
  <valueSet value="http://hl7.org/fhir/ValueSet/research-study-phase"/> 
  <content value="complete"/> 
  <concept> 
    <code value="n-a"/> 
    <display value="N/A"/> 
    <definition value="Trials without phases (for example, studies of devices or behavioral interventions)."/> 
  </concept> 
  <concept> 
    <code value="early-phase-1"/> 
    <display value="Early Phase 1"/> 
    <definition value="Designation for optional exploratory trials conducted in accordance with the United
     States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational
     New Drug (IND) Studies. Formerly called Phase 0."/> 
  </concept> 
  <concept> 
    <code value="phase-1"/> 
    <display value="Phase 1"/> 
    <definition value="Includes initial studies to determine the metabolism and pharmacologic actions
     of drugs in humans, the side effects associated with increasing doses, and to gain
     early evidence of effectiveness; may include healthy participants and/or patients."/> 
  </concept> 
  <concept> 
    <code value="phase-1-phase-2"/> 
    <display value="Phase 1/Phase 2"/> 
    <definition value="Trials that are a combination of phases 1 and 2."/> 
  </concept> 
  <concept> 
    <code value="phase-2"/> 
    <display value="Phase 2"/> 
    <definition value="Includes controlled clinical studies conducted to evaluate the effectiveness of
     the drug for a particular indication or indications in participants with the disease
     or condition under study and to determine the common short-term side effects and
     risks."/> 
  </concept> 
  <concept> 
    <code value="phase-2-phase-3"/> 
    <display value="Phase 2/Phase 3"/> 
    <definition value="Trials that are a combination of phases 2 and 3."/> 
  </concept> 
  <concept> 
    <code value="phase-3"/> 
    <display value="Phase 3"/> 
    <definition value="Includes trials conducted after preliminary evidence suggesting effectiveness of
     the drug has been obtained, and are intended to gather additional information to
     evaluate the overall benefit-risk relationship of the drug."/> 
  </concept> 
  <concept> 
    <code value="phase-4"/> 
    <display value="Phase 4"/> 
    <definition value="Studies of FDA-approved drugs to delineate additional information including the
     drug's risks, benefits, and optimal use."/> 
  </concept> 
</CodeSystem>